Search hospitals > British Columbia > VANCOUVER

Vancouver General Hospital

Claim this profile
VANCOUVER, British Columbia V5Z 1M9
Global Leader in Stroke
Global Leader in Heart Attack
Conducts research for Atrial Fibrillation
Conducts research for Heart Failure
Conducts research for Cancer
290 reported clinical trials
30 medical researchers
Photo of Vancouver General Hospital in VANCOUVERPhoto of Vancouver General Hospital in VANCOUVERPhoto of Vancouver General Hospital in VANCOUVER

Summary

Vancouver General Hospital is a medical facility located in VANCOUVER, British Columbia. This center is recognized for care of Stroke, Heart Attack, Atrial Fibrillation, Heart Failure, Cancer and other specialties. Vancouver General Hospital is involved with conducting 290 clinical trials across 471 conditions. There are 30 research doctors associated with this hospital, such as David A Wood, MD, Jacqueline Saw, MD, Ben Chew, MD, and Thalia Field, MD.

Top PIs

Clinical Trials running at Vancouver General Hospital

Stroke
Atrial Fibrillation
Chronic Obstructive Pulmonary Disease
Idiopathic Pulmonary Fibrosis
Heart Attack
Obesity
Coronary Artery Dissection
Coronary Artery Disease
Non-Hodgkin's Lymphoma
Acute Lymphoblastic Leukemia
Image of trial facility.

Blood Thinners

for Atrial Fibrillation

This trial is testing whether taking blood-thinning pills can prevent strokes and other heart issues in patients who have temporary irregular heartbeats and are at risk of stroke after surgery. These pills are a recent breakthrough in preventing strokes.
Recruiting3 awards Phase 44 criteria
Image of trial facility.

Milvexian

for Stroke

This trial is testing whether milvexian can help prevent another stroke in people who have already had one by stopping blood clots from forming. Milvexian may reduce the risk of stroke without significant bleeding.
Recruiting1 award Phase 35 criteria
Image of trial facility.

Recombinant Factor VIIa

for Hemorrhagic Stroke

The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 180 days as measured by the Modified Rankin Score (mRS) and decrease ongoing bleeding as compared to standard therapy. FASTEST Part 2 is an extension of the FASTEST Trial where the subgroups include only those treated within 2 hours with a positive spot sign on a baseline CT angiogram.
Recruiting1 award Phase 32 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Vancouver General Hospital?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security